There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Coherus Biosciences (CHRS) and BioDelivery (BDSI) with bullish sentiments.
Coherus Biosciences (CHRS)
H.C. Wainwright analyst Jason Kolbert reiterated a Buy rating on Coherus Biosciences today and set a price target of $28. The company’s shares closed yesterday at $11.93.
Kolbert observed:
“We think of the UDENYCA launch as the roll-out of a branded drug (and not just another generic). Coherus ended the period with $117M in cash.”
According to TipRanks.com, Kolbert is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.2% and a 37.3% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Can-Fite BioPharma.
Currently, the analyst consensus on Coherus Biosciences is a Strong Buy with an average price target of $32.67, which is a 173.8% upside from current levels. In a report issued on November 2, Maxim Group also maintained a Buy rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
BioDelivery (BDSI)
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on BioDelivery today and set a price target of $5. The company’s shares closed yesterday at $3.69.
Livnat commented:
“We reiterate our Buy rating and DCF-based $5 price target which implies an approximate $450M EV, just a 5x multiple on our 2019 REV, which is not particularly generous at this early stage in a growth story. 3Q18 results and estimates. BDSI total revenue of $14.2M vs. our/ Street $15.1/13.9M.”
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 7.0% and a 59.1% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Agile Therapeutics, and Cara Therapeutics.
BioDelivery has an analyst consensus of Strong Buy, with a price target consensus of $4.83, a 30.9% upside from current levels. In a report issued on October 26, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $4.50 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
